当前位置: 首页 > 期刊 > 《中国当代医药》 > 2012年第30期
编号:12328424
齐拉西酮注射液治疗精神分裂症激越症状的研究(3)
http://www.100md.com 2012年10月25日 《中国当代医药》 2012年第30期
     [4] Daniel D,Brook S,Benattia I. Transition from IM to oral ziprasidone:Clinical efficacy and safety data[C]. Presented at the 155th Annual Meeting of the American Psychiatric Association,2002.

    [5] Danil DG,Potkin SG,Reeves KR,et al. Intramuscular Ziprasidone 20mg is effective in reducing acute agitation associated with psychosis:a double blind,randomized trial[J]. J. Psychopharmacology,2001,155(2):128-134.

    [6] Keck PE,Versiani M,Potkin S, et al. Intramuscular Ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis[J]. J. Clin Psychiatry,2000,61(12):933-941.

    [7] Vieweg WV,Hasnain M. Ziprasidone and QTc Interval Prolongation in the ZODIAC Study[J]. The American Journal of Psychiatry,2011,168(6):650-651.

    [8] Strom BL,Eng SM,Faich G,et al. Comparative Mortality Associated with Ziprasidone and Olanzapine in Real-World use Among 18,154 Patients with schizophrenia[J]. The American Journal of Psychiatry,2011,168(2):193-201.

    [9] 张疆莉,张建红,申彪. 齐拉西酮注射液与氟哌啶醇注射液治疗急性精神分裂症的疗效及安全性比较[J]. 中国现代药物应用,2010,4(12):126-127.

    [10] 何俊,王玉文,王泽民. 齐拉西酮研究进展[J]. 医药导报,2011,30(12):1613-1615.

    [11] 黄继忠,江开达,司天梅. 齐拉西酮治疗精神分裂症临床应用指导建议[J]. 中国新药与临床杂志,2011,30(9):641-649.

    (收稿日期:2012-09-06 本文编辑:郭静娟), 百拇医药(尹析凡 王刚)
上一页1 2 3